1832 Asset Management L.P. Raises Position in Alnylam Pharmaceuticals, Inc. $ALNY

1832 Asset Management L.P. grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 55.1% in the second quarter, HoldingsChannel reports. The fund owned 223,345 shares of the biopharmaceutical company’s stock after purchasing an additional 79,300 shares during the quarter. 1832 Asset Management L.P.’s holdings in Alnylam Pharmaceuticals were worth $72,831,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of ALNY. Evelyn Partners Investment Management LLP grew its holdings in Alnylam Pharmaceuticals by 11.5% during the second quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 30 shares during the period. Bayforest Capital Ltd raised its stake in shares of Alnylam Pharmaceuticals by 14.6% in the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 39 shares during the period. MAI Capital Management lifted its position in shares of Alnylam Pharmaceuticals by 9.2% during the 2nd quarter. MAI Capital Management now owns 488 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 41 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Alnylam Pharmaceuticals by 32.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 44 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 13,170 shares of the biopharmaceutical company’s stock worth $4,295,000 after acquiring an additional 45 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the sale, the executive vice president owned 54,052 shares in the company, valued at $24,434,206.60. This represents a 6.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 78,328 shares of company stock worth $35,705,793 over the last three months. 1.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ALNY. HC Wainwright set a $570.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 4th. Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Barclays upped their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Bank of America raised their price target on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Finally, JPMorgan Chase & Co. dropped their price objective on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research note on Monday, October 13th. Twenty-three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $482.17.

Alnylam Pharmaceuticals Trading Up 1.8%

Shares of Alnylam Pharmaceuticals stock opened at $473.29 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The business has a 50-day moving average price of $456.23 and a 200-day moving average price of $400.63. The firm has a market cap of $62.53 billion, a price-to-earnings ratio of 1,972.04 and a beta of 0.30.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.